Related Experiment Videos
[Clinical evaluation of sultamicillin fine granules in pediatric infections]
Abstract:
Sultamicillin fine granules (SBTPC), a mutual prodrug of sulbactam (SBT) and ampicillin (ABPC), were administered to 16 pediatric patients with bacterial infections. The efficacy rate was 93.3%. MICs (10(6) cells/ml) of SBTPC against beta-lactamase non-producing strains were not significantly different from those of ABPC, and ranged from less than or equal to 0.05 to 1.56 micrograms/ml. MICs of SBTPC, however, were 2-4 fold smaller than MICs of ABPC against beta-lactamase producing strains. Diarrhea and loose stool as side effects were observed in 4 (25%) of 16 patients, but none of them were severe. After oral administration of SBTPC (10 mg/kg), serum levels of ABPC and SBT peaked at 3.41 micrograms/ml and 2.43 micrograms/ml after 0.6 hour, and declined with half-lives of 1.79 and 1.00 hours, respectively.
Insights
Sultamicillin fine granules (SBTPC) effectively treated bacterial infections in children, showing high efficacy and improved activity against resistant strains. Side effects were mild, with good absorption observed in pediatric patients.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antimicrobial Agents
Context:
- Bacterial infections pose a significant threat to pediatric populations.
- Beta-lactamase producing bacteria present a challenge for traditional antibiotic therapies.
- Sultamicillin fine granules (SBTPC) offer a combination therapy approach.
Purpose:
- To evaluate the efficacy and safety of sultamicillin fine granules (SBTPC) in pediatric patients with bacterial infections.
- To assess the in vitro antimicrobial activity of SBTPC compared to ampicillin (ABPC) against various bacterial strains.
- To determine the pharmacokinetic profile of SBTPC following oral administration in children.
Summary:
- SBTPC demonstrated a high efficacy rate of 93.3% in treating pediatric bacterial infections.
- In vitro studies showed SBTPC had comparable or enhanced activity against beta-lactamase producing strains versus ABPC.
- The drug was well-tolerated, with mild gastrointestinal side effects reported in 25% of patients. Pharmacokinetic analysis revealed rapid absorption and elimination of ampicillin and sulbactam.
Impact:
- SBTPC represents a viable therapeutic option for pediatric bacterial infections, particularly those involving beta-lactamase producing organisms.
- The favorable safety and pharmacokinetic profile supports its use in pediatric clinical practice.
- Further research could explore broader applications and comparative effectiveness against other antibiotic regimens.